Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192510 | 0.79 | CTSA (0.39) | SLC2A1MAPK14CTSACDK2KDM4E | |
| SCHEMBL2188610 | 0.78 | MAPK14 (0.39) | SLC2A1MAPK14CTSACDK2LMNA | |
| SCHEMBL5033486 | 0.77 | CDK2 (0.49) | SLC2A1MAPK14CTSACDK2PRMT5 | |
| SCHEMBL2219082 | 0.76 | MAPK14 (0.38) | SLC2A1MAPK14CTSACDK2LMNA | |
| SCHEMBL2217811 | 0.74 | CTSA (0.39) | SLC2A1MAPK14CTSACDK2LMNA | |
| SCHEMBL14032681 | 0.73 | ALDH1A1 (0.40) | MAPK14CTSACDK2LMNAKDM4E | |
| SCHEMBL13373326 | 0.70 | SMN1; SMN2 (0.41) | SLC2A1PRMT5KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30437840 | 0.69 | SMN1; SMN2 (0.47) | LMNAKDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL2008301 | 0.68 | ALDH1A1 (0.45) | MAPK14CTSACDK2LMNAKDM4E | |
| SCHEMBL28933357 | 0.67 | LMNA (0.52) | SLC2A1LMNAKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519522-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | SLC2A1 2458/4885MAPK14 3207/4885CTSA 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.